U.S. Software Stock News

Gogoro Inc.'s ( NASDAQ:GGR ) price-to-sales (or "P/S") ratio of 6.1x may look like a poor investment opportunity when...

We wouldn't blame IDT Corporation ( NYSE:IDT ) shareholders if they were a little worried about the fact that Abilio...

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Aardvark Therapeutics, Inc. ( NASDAQ:AARD ) insiders who purchased shares in the last 12 months were richly rewarded...

Willdan Group (NASDAQ:WLDN) has had a great run on the share market with its stock up by a significant 27% over the...

Capri Holdings Limited ( NYSE:CPRI ) shareholders should be happy to see the share price up 14% in the last quarter...

If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'd...

With a price-to-earnings (or "P/E") ratio of 54.9x Materialise NV ( NASDAQ:MTLS ) may be sending very bearish signals...

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Bakkt Holdings recently completed the sale of its loyalty business and appointed fintech veteran Mike Alfred to its board, marking a shift to a focused digital asset infrastructure platform. This transformation is underscored by renewed emphasis on Bitcoin, tokenized payments, and zero debt, signaling a significant realignment toward crypto and digital finance services. We'll explore how the company’s sharpened focus on digital assets and new leadership shapes Bakkt Holdings' investment...

If you are tracking UMH Properties and wondering whether now is the right time to act, you are not alone. The stock has had a bumpy ride lately, dipping by 1.0% over the past week and dropping 4.4% in the last month. Zoom out a bit further, and the year-to-date decline sits at 22.9%, with a 19.4% loss over the past year. Still, long-term investors will notice that the three-year return is up 11.6%, and the five-year gain stands at 26.9%, so this is a company that has seen both turbulence and...

If you are watching Kinetik Holdings and wondering whether now is the right moment to act, you are definitely not alone. The stock has driven quite a debate this year, down 34.4% since January and recently sliding another 15.4% this past week. Despite these short-term headwinds, it is striking to note that investors who have held on for three years are still up by 40.7%. With a last close at $38.56, Kinetik’s price chart has been anything but boring. These moves have not come out of nowhere...

If you are staring at Fulton Financial’s ticker and wondering what comes next, you are not alone. The stock has quietly caught the eye of both cautious and optimistic investors after years of solid, if occasionally bumpy, performance. While volatility has crept in recently, with the price slipping -2.9% in the past week and -5.3% over the last month, the longer-term story is hard to ignore. Shares are up 10% over the past year, and an impressive 118.3% over five years, which suggests that...

If you have been watching Pitney Bowes lately, you are probably wondering what to make of its rollercoaster stock chart. Is now the moment to buy, or should you stay on the sidelines? The fact is, this is a company whose shares have caught a wave of renewed interest, and investors are kicking the tires to see if there is more room to run or if the brakes are about to hit. Over just the past year, Pitney Bowes has soared 65.1%, and if you zoom out a little more, the stock has posted a...

Alto Neuroscience just received Fast Track designation from the FDA for ALTO-101, a new drug candidate aimed at treating cognitive impairment related to schizophrenia. This move could accelerate ALTO-101’s development and review process. See our latest analysis for Alto Neuroscience. The FDA’s support for ALTO-101 sparked fresh interest in Alto Neuroscience. However, despite the headline, its 1-year total shareholder return remains nearly flat while recent share price momentum has been...

Thinking about what to do next with Brookdale Senior Living stock? You are definitely not alone. Investors have watched this name closely, and its recent movements may have complicated your decision a bit. The stock closed at $8.06, taking a small dip of -3.4% over the past week. But step back and you will see some remarkable momentum: up 4.8% for the month, and a whopping 59.3% so far this year. That adds to a powerful longer-term trend. Brookdale shares have climbed nearly 188% over the...

If you own shares of Equity Residential or are thinking about adding it to your watchlist, you are probably wondering if now is a good time to buy, sell, or hold. With the stock closing recently at $63.3, it might look like the company is stuck in a holding pattern. After all, the stock is down 1.9% over the last week and off 5.3% for the month. Even looking back over the year, it has slipped 10.4%, missing out on some momentum that has lifted other corners of the market. However, when you...

Trying to decide what to do with Chemed stock right now? You are not alone. Shareholders and would-be investors alike have been watching the company’s journey with a mix of curiosity and concern. After all, Chemed’s story over the past year has not followed a gentle upward climb. Instead, it has seen some notable slides, including a 16.0% drop year-to-date and an even steeper 23.4% decline over the past 12 months. Even stretching out to five years, Chemed’s shares are down 5.9%, which can...

Thinking about your next move with American Homes 4 Rent? You are not alone. The real estate sector has kept investors guessing lately, and American Homes 4 Rent has seen its fair share of ups and downs. Over the past week, the stock held steady with a slight 0.1% bump, but the 30-day drop of 6.3% and a year-to-date slide of 11.2% might be giving some pause. Long-term holders have still netted a gain, with more than 22% over five years, but recent dips have many wondering whether there is...

In recent weeks, ProAssurance received a consensus "Hold" recommendation from six ratings firms, while Zacks Research raised its rating to "strong-buy" and institutional investors and hedge funds significantly increased their shareholdings. This combination of analyst upgrade and heightened institutional interest signals a shift in market sentiment and renewed confidence in the company’s outlook. We’ll examine how the increased institutional ownership may impact ProAssurance’s investment...

Thinking about making a move with Pinnacle West Capital? You are not alone. The stock has caught more attention lately, pushing up 3.9% over the past week and up 1.3% in the last month. Year to date, Pinnacle West Capital is sitting at a 7.0% gain and is up 6.7% over the past year. If you have been holding on for a while, the ride has been even better, with a substantial 68.9% return across three years and 36.3% over five years. What is driving this? Many investors are attributing the recent...

If you have been eyeing Slide Insurance Holdings or already hold some shares, you are probably wondering whether now is a smart time to buy, sell, or simply sit tight. The stock has certainly been on the move, with prices rising 5.2% over the past week and up 14.8% in the last month. That momentum stands in stark contrast to its year-to-date performance, where shares are still down 22.3%. This kind of turnaround often hints at shifting investor sentiment, possibly tied to developments in the...

Wondering whether Victory Capital Holdings is a buy, a sell, or a hold after another roller-coaster month? You are not alone. For anyone tracking the stock’s moves, the past year has been quite the ride: up 16.8% over twelve months, climbing a remarkable 308.8% over five years, but giving back some ground with an 8.5% dip in the past 30 days. Just last week, shares edged down by 0.5%, reflecting shifting market sentiment rather than any headline-shaking news. With momentum this strong over...

LENZ Therapeutics (LENZ) has just announced that VIZZ, its newly FDA-approved aceclidine-based eye drop for presbyopia, is now being distributed to eye care professionals across the United States. Consumer availability is set for October, and retail expansion will follow soon. See our latest analysis for LENZ Therapeutics. With VIZZ now hitting the market, LENZ Therapeutics is in the spotlight, and the recent commercial launch has stirred up investor interest. Over the past year, the total...